|
|
|
|
|
| Effect of low dose vasopressin on the level of blood lactic acid and the progression of renal failure in patients with septic shock |
| Li Hai, Zhang Hai-bo, Song Ling-li, Han Ming |
| Department of Emergency, Central Hospital of Zibo, Zibo 255000, China |
|
|
|
|
Abstract Objective To compare the effect of low dose vasopressin on the level of blood lactic acid and the progression of renal failure in patients with septic shock. Methods One hundred patients with septic shock from May 2015 to August 2017 were randomly divided into two groups. The two groups were given a consistent expansion, antibiotics, nutritional support, norepinephrine and other basic treatment measures. One group was treated with a small dose of vasopressin (observation group). The other group was set as a control group.After treatment, the difference of serum lactic acid level, renal function index, hemodynamic index, ICU time of hospitalization and mortality during hospitalization at different time in two groups were analyzed. Results After treatment, the level of blood lactic acid decreased gradually in the two groups.But after treatment, the level of blood lactate in the observation group was significantly lower than that of the control group at all time points,and the differences were statistically significant (P<0.05).After the treatment of 24 h, the level of SCr and BUN continued to rise in two groups. But the increase of the observation group was significantly smaller than that of the control group (P<0.05).The amount of urine in the two groups was more than that before the treatment; after the treatment of 24 h, the indexes of renal function in the observation group were obviously superior to those of the control group, and the differences were statistically significant. After the treatment of 24 h, both groups of MAP increased and HR decreased in all two groups,the difference was statistically significant compared with that before treatment(P<0.05). CO value did not change significantly (P>0.05). After treatment, the improvement of MAP and HR in the observation group was larger than that of the control group(P<0.05).The time of ICU hospitalization in the two groups was consistent.Some patients died during the hospital stay,and there was no statistically significant difference in mortality(P>0.05). Conclusion Vasopressin can be used in combined treatment regimens in patients with septic shock for basic therapeutic treatment.
|
|
|
|
Corresponding Authors:
Zhang Hai-bo, E-mail: zhhb6803@163.com
|
|
|
|
| ［1］牛莎, 张睢扬. 脓毒症和脓毒症休克抗感染治疗进展［J］. 中华肺部疾病杂志（电子版）, 2013, 6(3):1-3.
［2］Reinhart K, Sakka SG, Meier-Hellmann A. Haemodynamic management of a patient with septic shock［J］. Eur J Anaesthesiol, 2000, 17(1):6-17.
［3］中华医学会重症医学分会. 中国严重脓毒症/脓毒性休克治疗指南(2014)［J］. 全科医学临床与教育, 2015, 54(4):365-367.
［4］金灵燕, 范开亮, 方华,等. 脓毒症休克血管活性药物研究进展［J］. 现代临床医学, 2017, 43(4):243-245,250.
［5］Annane D, Bellissant E, Sebille V, et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve［J］. Br J Clin Pharmacol, 1998, 46(6):589-597.
［6］高戈, 冯喆, 常志刚,等. 2012国际严重脓毒症及脓毒性休克诊疗指南［J］. 中华危重病急救医学, 2013, 25(8):501-505.
［7］Conrad M, Perez P, Thivilier C, et al. Early prediction of norepinephrine dependency and refractory septic shock with a multimodal approach of vascular failure［J］. J Crit Care, 2015, 30(4):739-743.
［8］朱国超, 崔军凯, 吴文良,等. 去甲肾上腺素联合艾司洛尔对脓毒症休克的治疗［J］. 实用医学杂志, 2015, 31(22):3778-3780.
［9］邓振忠, 赵允召. 去甲肾上腺素在脓毒症休克中的应用进展［J］. 医学研究生学报, 2009, 22(3):311-314.
［10］Minasyan H. Sepsis and septic shock: Pathogenesis and treatment perspectives［J］. J Crit Care, 2017, 40:229-242.
［11］Beloborodova NV, Sarshor YN, Bedova AY, et al. Involvement of aromatic metabolites in the pathogenesis of septic shock［J］. Shock, 2017.［Epub ahead of print］
［12］Du Y, Wang L, Shi H, et al. Comparison of clinical effect of dopamine and norepinephrine in the treatment of septic shock［J］. Pak J Pharm Sci, 2015, 28
(4 Suppl):1461-1464.
［13］Gélo n A, Pichot C, Leroy S, et al. Pressor response to noradrenaline in the setting of septic shock: Anything new under the sun-dexmedetomidine, clonidine A minireview［J］. Biomed Res Int, 2015, 2015:863 715.［14］方晓君. 血管加压素使用时机和脓毒性休克的死亡率:队列研究［J］. 创伤与急诊电子杂志, 2016,6(2):123.
［15］赵贤元,皋源,杭燕南,等.感染性休克患者血管加压素血浆浓度及临床相关因素的分析［J］.临床麻醉学杂志,2011,27(9):921-922.
［16］李乐, 谭奕东, 韦琪. 不同剂量血管加压素对脓毒症难治性休克患者血流动力学的影响［J］. 河北医学, 2015, 21(9):1446-1449.
［17］Xiao X, Zhang J, Wang Y, et al. Effects of terlipressin on patients with sepsis via improving tissue blood flow［J］.J Surg Res, 2016, 200(1):274-282.
［18］Avni T, Lador A, Lev S, et al. Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis［J］. PLoS One, 2015, 10(8):e0129 305.
［19］Choudhury A, Kedarisetty CK, Vashishtha C, et al. A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock［J］. Liver Int, 2017, 37(4):552-561.
［20］íma M, Pokorn M, Pa our F, et al. Terlipressin Induced Severe Hyponatremia［J］. Prague Med Rep, 2016, 117(1):68-72.
［21］Sanghi K. Serendipitous use of terlipressin［J］. Anaesth Intensive Care, 2016, 44(1):119.
［22］Ida KK, Otsuki DA, Sasaki AT, et al. Effects of terlipressin as early treatment for protection of brain in a model of haemorrhagic shock［J］. Crit Care, 2015, 19:107.
［23］Xiao X, Zhu Y, Zhen D, et al. Beneficial and side effects of arginine vasopressin and terlipressin for septic shock［J］. J Surg Res, 2015, 195(2):568-579.
［24］He X, Su F, Silvio TF, et al. A selective V1A receptor agonist, selepressin, is superior to arginine vasopressin and to norepinephrine in ovine septic shock［J］. Crit Care Med, 2016, 44(1):23-31.
［25］Thomas-Rueddel DO, Poidinger B, Weiss M, et al. Hyperlactatemia is an independent predictor of mortality and denotes distinct subtypes of severe sepsis and septic shock［J］. J Crit Care, 2015, 30(2):439.
［26］吴趋, 誉铁鸥. 小剂量血管加压素联合去甲肾上腺素对脓毒症难治性休克患者血乳酸的影响［J］. 中西医结合心血管病电子杂志, 2014,9(5):120-121.
［27］喻文, 罗红敏. 早期使用血管加压素或去甲肾上腺素对感染性休克患者肾功能衰竭的影响:VANISH随机临床试验［J］. 中华危重病急救医学, 2016, 28(12):1094.
［28］Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: The VANISH randomized clinical trial［J］. JAMA, 2016, 316(5):509-518. |
|
|
|
Address: 1 North 2nd Street,
Zhongguancun, 
